# Pizarra — PT-pseudo_37d8ae9b27f1 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_37d8ae9b27f1
Task: 1

Encounter: Urology - outpatient on 18 Jan 2025.
Referrer: Dr. S. de Vries (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 4.8 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.053 ng/mL²
  - PSA velocity: 0.39 ng/mL/yr
  - Prior PSA: 4.7 ng/mL
  - Prostate volume: 90.82 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.46945655 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 4.8 ng/mL. PI-RADS 4. PSAD 0.05. Prostate volume 91 mL. csPCa 0.47.

Vitals: weight 76 kg, height 180 cm, BMI 23.5, BP 120/76 mmHg, HR 79 bpm. Smoking: Non-smoker.

Chief complaint: Clinical attention sought due to a previous prostate cancer diagnosis coupled with a recent serum PSA rise to 4.8 ng/mL.

History: At sixty-seven years of age, this widowed patient has a documented history of a prior positive biopsy confirming low-grade malignancy. Initial evaluation for an elevated PSA occurred in 2022. He experiences moderate lower urinary tract symptoms, scoring 16 on the IPSS questionnaire, dominated by nocturia and a diminished urinary stream that have not progressed recently. Occupational background includes work as a retired mechanical engineer. He resides independently. Lifestyle factors include being a Non-smoker, consuming six alcoholic units weekly, and participating in weekly swimming sessions. Past medical encounters involve standard audiology and vascular surgery visits for unrelated aging processes, with no other significant comorbidities or active medications reported. He explicitly denies bone discomfort, haematuria, or constitutional complaints.

Physical examination: Normal DRE: Symmetrically enlarged gland exhibiting a uniform, smooth consistency without focal hardening or asymmetry. Systemic inspection shows stable hemodynamic parameters, clear lung fields, and absence of peripheral edema or palpable lymph nodes.

Patient info: retired mechanical engineer; Widowed; Lives alone.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 6 units / week; exercise Swimming 1x/week; IPSS score: 16/35 (moderate LUTS).

Recent other appointments: Audiology — hearing test; Vascular surgery — varicose veins consult.
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.59 +/- 0.24   (95% CI 0.11-1.00)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.24  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.98 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'discuss': p +/- dp straddles 0.5. The classifier genuinely CANNOT tell the two answers apart here. Its number is a starting point only. Measured accuracy in this tier on the labelled cohort: 0.488 over 43 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the current mpMRI lesion size/zone compare against an earlier study?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend beyond the headline value of 4.8 ng/mL?
  - previous_notes (get_previous_notes) -> What was the prior grade, surveillance pathway, and management agreement?

This case hinges on the retrieved documents to determine if the prior positive biopsy status, combined with the current PSA rise and imaging findings, warrants a biopsy decision, as the initial panel is inconclusive. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical model only weighed the structured panel, failing to incorporate the context that the prior biopsy was positive, which fundamentally changes the question from "does he have cancer?" to "is the existing lesion stable or progressed?" Specifically, the prior positive biopsy status is a critical piece of information that the classifier did not weigh against the current PSA rise (4.8 ng/mL) and the PI-RADS 4 score. Furthermore, the model did not account for the specific PSA density (0.053 ng/mL²) or the specific guideline criteria related to the PI-RADS 4 score in conjunction with the prior diagnosis.

WHY THE SUGGESTION COULD BE WRONG
The prior positive biopsy status suggests that the decision should pivot away from a simple "yes/no" based on current metrics. The statistical prior suggested BIOPSY (p=0.59), which is highly susceptible to being wrong because the guideline criterion explicitly states the panel is inconclusive and requires retrieved documents. The high aleatoric uncertainty (H=0.98) indicates the model cannot distinguish between the two outcomes given the input, suggesting the suggestion is based on insufficient context regarding the prior diagnosis.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
psa_trend - What is the serial PSA trend beyond the headline value of 4.8 ng/mL?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?

GUIDELINE ANCHOR
The guideline states that the visible panel does not determine the decision because the decision must come from retrieved documents regarding prior grade, lesion change, and surveillance pathway.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_37d8ae9b27f1", "radiology_report": "PI-RADS 4 lesion in the left peripheral zone. Prostate volume 90.82 mL yielding a PSA density of 0.053 ng/mL/mL. csPCa predicted probability 0.46945655"}
get_psa_trend
[{"date": "Aug 2022", "val": 3.6}, {"date": "May 2023", "val": 1.2}, {"date": "Mar 2024", "val": 3.1}, {"date": "Jan 2025", "val": 4.8}]
get_previous_notes
[{"date": "23 May 2024", "author": "Dr. S. de Vries (GP)", "text": "28 July 2023 - Dr. S. de Vries (GP): Clinical review focused on the evolving PSA profile. The latest measurement registers at 4.1 ng/mL, reflecting a steady increase from the initial baseline. The clinical team will maintain standard surveillance protocols."}, {"date": "28 Jul 2023", "author": "Dr. S. de Vries (GP)", "text": "23 May 2024 - Dr. S. de Vries (GP): Laboratory analysis demonstrates a subsequent PSA increase to 4.7 ng/mL. Considering the documented history of a previously positive biopsy alongside this sustained elevation, a urology re-evaluation was initiated. The patient received notification regarding the outpatient appointment."}]
NOT RETRIEVED
laboratory_results
Left closed because the moderator's agenda did not explicitly require the full lab panel, and the retrieved documents provided sufficient context regarding PSA trajectory and prior management.
WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- PSA trend shows a significant rise from 3.1 ng/mL (Mar 2024) to 4.8 ng/mL (Jan 2025).
- The MRI shows a PI-RADS 4 lesion in the left peripheral zone, which is a known area of concern.
- Previous notes confirm a prior positive biopsy and a re-evaluation was initiated due to sustained elevation.
AGAINST sampling this patient now:
- Prior biopsy confirmed low-grade malignancy.
- DRE findings are Normal.
- No information on whether the lesion size/zone has changed since the 2021 MRI.
WHERE THIS LEANS
The evidence suggests a need for further investigation due to the rising PSA and the presence of a PI-RADS 4 lesion, which aligns with the guideline criterion that requires reviewing retrieved documents.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=abstains, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved documents (PSA trend showing a rise to 4.8, MRI showing PI-RADS 4, and previous notes confirming prior positive biopsy) provide sufficient context for the guideline criterion to be applied, leading to a lean towards biopsy.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision leans toward biopsy because the prior positive biopsy status, combined with the rising PSA trend from 3.1 ng/mL to 4.8 ng/mL and the presence of a PI-RADS 4 lesion, provides sufficient context to warrant further investigation. The statistical prior suggested biopsy, and the retrieved evidence confirmed the need to review these factors against the guideline criterion. The conference converged on proceeding with biopsy because the retrieved documents indicated a need to assess the existing lesion further.

Variables that carried weight: bx=decisive, age=important, psa=important, vol=noted, psad=important, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
